SOURCE: Aldeyra Therapeutics

Aldeyra Therapeutics

February 06, 2017 08:00 ET

Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day

LEXINGTON, MA--(Marketwired - Feb 6, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017.

Event: 2017 Rare Disease, Biopharma One-on-One Day
Date: Tuesday, February 7, 2017
Location: Intercontinental Barclay, 111 E 48th St, New York, NY

About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Contact Information

  • Corporate Contact:
    Stephen Tulipano
    Aldeyra Therapeutics, Inc.
    Tel: +1 781-761-4904 ext. 205
    Email Contact

    Investor Contact:
    Chris Brinzey
    Westwicke Partners
    Tel: 339-970-2843
    Email Contact

    Media Contact:
    Cammy Duong
    MacDougall Biomedical Communications
    781-591-3443
    Email Contact